Skip Navigation



Carcinogenesis Advance Access published online on August 12, 2004
Carcinogenesis, doi:10.1093/carcin/bgh256
© 2004 by Oxford University Press
This Article
Right arrow Advance Access manuscript (PDF) Freely available
Right arrow All Versions of this Article:
25/12/2319    most recent
bgh256v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Schlichtholz, B.
Right arrow Articles by Matuszewski, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schlichtholz, B.
Right arrow Articles by Matuszewski, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Received May 7, 2004
Revised July 7, 2004
Accepted August 2, 2004

CANCER BIOLOGY

Clinical implications of p53 mutation analysis in bladder cancer tissue and urine sediment by functional assay in yeast

Beata Schlichtholz 1*, Malgorzata Presler 1, Marcin Matuszewski 2

1 Department of Biochemistry, Medical University of Gdansk, Gdansk, Poland
2 Department of Urology, Medical University of Gdansk, Gdansk, Poland

* To whom correspondence should be addressed. E-mail: bsch{at}amg.gda.pl.


  Abstract

In the present study we correlate the p53 gene mutations in tumour tissue with urine sediment using functional assay in yeast, and relate the p53 status to outcome in a group of patients with transitional cell carcinoma of the bladder. The p53 mutations were found in 3 of 30 (10%) Ta/T1 tumour tissue samples and in 2 of 20 (10%) corresponding urine sediments. In the stage T2-T4 tumour p53 mutations were found in tumour tissues and urine sediments in 13 of 31 (42%) and in 7 of 18 (39%) samples, respectively. In 80% (8/10) of cases, the p53 mutations found in tumour tissue were re-detected in urine sediment. Median follow-up was 20 months. Disease recurred in 18 of the 61 patients (30%) with a median time of 5 months. In Ta/T1 tumours the frequency of recurrence was 37% (11/30) comparing to 23% (7/31) of T2-T4 tumours. The 3-year overall survival was 82% (50/61). The p53 status was significantly associated with stage (P = 0,0077, two-sided Fisher's exact test), grade (P < 0,001), and lymph node involvement (P = 0,027). There was an association between the p53 mutations and shorter overall survival (P = 0,033; log-rank test), however in a multivariate analysis adjusted for stage, grade, lymph node status, and age the p53 mutation was not an independent predictor of survival. There was no correlation of the p53 status with decreased disease-free survival (P = 0,8; log-rank test). The data presented indicate that yeast functional assay is a useful method for p53 gene mutation analysis in tumour tissue and p53 mutation can be re-detected in urine sediment, but further validation of the assay in non-invasive screening for p53 mutations is needed.

Keywords: bladder cancer; p53 mutations; urine sediment; survival; recurrence.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.